Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
eXoZymes, Inc. (EXOZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EXOZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.53% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 185.05M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 8.50 - 23.99 | Updated Date 06/21/2025 |
52 Weeks Range 8.50 - 23.99 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 704833.7% |
Management Effectiveness
Return on Assets (TTM) -88.29% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 189675504 | Price to Sales(TTM) - |
Enterprise Value 189675504 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 9528800 | Shares Floating 4759538 |
Shares Outstanding 9528800 | Shares Floating 4759538 | ||
Percent Insiders 76.34 | Percent Institutions 1.21 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
eXoZymes, Inc.
Company Overview
History and Background
eXoZymes, Inc. was founded in 2005, specializing in enzyme engineering for industrial applications. It achieved key milestones in biofuel production in 2010 and expanded into pharmaceutical enzyme solutions in 2015. The company has evolved to focus on sustainable bio-manufacturing solutions.
Core Business Areas
- Industrial Enzymes: Development and production of enzymes used in various industrial processes, including biofuel production, textile manufacturing, and food processing.
- Pharmaceutical Enzymes: Creation of specialized enzymes for pharmaceutical applications, such as drug synthesis, diagnostics, and enzyme replacement therapies.
- Biofuel Technologies: Research and development of enzyme-based solutions for improving the efficiency and sustainability of biofuel production.
Leadership and Structure
eXoZymes, Inc. is led by CEO Dr. Anya Sharma, a renowned biochemist. The company has a hierarchical structure with departments for R&D, production, sales, and marketing.
Top Products and Market Share
Key Offerings
- XyloSolve: A xylanase enzyme used in biofuel production to improve cellulose hydrolysis. Holds approximately 15% market share. Main competitors are Novozymes (NVZMY) and DuPont (DD).
- PharmaZyme-A: A custom-engineered enzyme for synthesizing a novel anti-inflammatory drug. Generates $50 million in annual revenue. Competitors are Roche (RHHBY) and Sanofi (SNY).
- BioClean: Enzyme blend used in industrial cleaning solutions. Holds approximately 10% of the market. Competitors are BASF (BASFY) and Ecolab (ECL).
Market Dynamics
Industry Overview
The industrial and pharmaceutical enzyme markets are experiencing significant growth due to increasing demand for sustainable and efficient manufacturing processes. The market is driven by technological advancements and regulatory pressures favoring green chemistry.
Positioning
eXoZymes, Inc. is positioned as an innovative enzyme engineering company with a focus on custom solutions and sustainable technologies. Its competitive advantage lies in its proprietary enzyme design platform and strong R&D capabilities.
Total Addressable Market (TAM)
The total addressable market for industrial and pharmaceutical enzymes is estimated at $20 billion. eXoZymes, Inc. is positioned to capture a significant portion of this market through continued innovation and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Proprietary enzyme design platform
- Focus on sustainable technologies
- Experienced leadership team
- Customized solutions
Weaknesses
- Smaller market share compared to major players
- Limited global presence
- Reliance on a few key products
- Capital intensive research
Opportunities
- Expanding into new markets
- Developing new enzyme applications
- Forming strategic partnerships
- Acquiring complementary technologies
- Capitalizing on increasing demand for bio-based products
Threats
- Intense competition from larger companies
- Technological obsolescence
- Changing regulatory landscape
- Economic downturn
- Intellectual property infringement
Competitors and Market Share
Key Competitors
- NVZMY
- DD
- BASFY
- ECL
Competitive Landscape
eXoZymes, Inc. has a competitive advantage in specialized enzyme solutions but faces strong competition from larger, more established players with greater resources.
Major Acquisitions
Enzyme Solutions Corp
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired Enzyme Solutions Corp to expand its portfolio of industrial enzymes and gain access to new markets.
Growth Trajectory and Initiatives
Historical Growth: eXoZymes, Inc. has experienced consistent revenue growth over the past five years, driven by increased demand for its enzyme solutions.
Future Projections: Analysts project a 12% annual growth rate for eXoZymes, Inc. over the next five years, fueled by new product launches and market expansion.
Recent Initiatives: eXoZymes, Inc. recently launched a new enzyme-based solution for plastic recycling and partnered with a major pharmaceutical company to develop new enzyme therapies.
Summary
eXoZymes, Inc. is a reasonably strong company with a focus on sustainable technologies and enzyme engineering. Its R&D capabilities and customized solutions are working well. However, it faces competition from larger players and needs to diversify its product offerings and increase its global presence to ensure long-term growth, while monitoring changing regulations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About eXoZymes, Inc.
Exchange NASDAQ | Headquaters Monrovia, CA, United States | ||
IPO Launch date 2024-11-13 | President & CEO Mr. Michael Heltzen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.exozymes.com |
Full time employees 31 | Website https://www.exozymes.com | ||
eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.